Cara Care

Cara Care develops a prescription digital health application (DiGA) for the treatment of irritable bowel syndrome (Reizdarm). The app guides users through a 12-week programme with content on basic knowledge, low-FODMAP nutrition, emotions and behaviour, symptom and food diaries, and audio-guided hypnosis exercises.

According to the website, the therapy is prescribed by doctors or applied for directly through statutory health insurers, which cover the cost (100 % per the site), and most private insurers also reimburse it depending on the tariff. The company also offers a prescription support service and in-app customer support. The site describes the product as CE-certified as a medical device and says it was developed with physicians and scientifically studied, with 70.2 % of study participants showing a clinically relevant symptom improvement.

The company states it was founded by physicians and has an international team based in Berlin. The site says it has been part of the Bayer group since 2025, and lists a job opening for a medical digital health working student (remote, Germany).

Product: Cara Care: a 12-week prescription digital therapy app (DiGA) for irritable bowel syndrome, with nutrition, behavioural and hypnosis content.